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560 Abstracts February 2014treatment was delayed by uncertainty regarding the source. In all three,
initial aneurysm dilatation was followed by shrinkage. The failed treatment
of a type I endoleak in a case of aortoiliac dissection resulted in the only
rupture in the entire series. Type II endoleaks were not treated.
Conclusions: Persistent aneurysm dilatation was a rare event after
endovascular repair using a multibranched endovascular stent graft, prob-
ably because most direct endoleaks (types I and III) were treated, whereas
untreated type II endoleaks appear to have had little effect on aneurysm size.
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Objectives: Dialysis patients with peripheral vascular disease (PVD)
are at high risk for complications after surgical bypass, and it is not clear if
endovascular interventions have affected survival and limb salvage in this pa-
tient population. We sought to characterize the outcomes of endovascular
(endo) and open revascularization in dialysis patients treated for claudica-
tion or critical limb ischemia (CLI).
Methods: The United States Renal Data System (USRDS) was used
to review all patients undergoing lower extremity revascularization (LER)
in dialysis patients in the United States between 2005 and 2008. Diagnoses
and procedures were identiﬁed by International Classiﬁcation of Diseases-
9th Revision and Current Procedural Terminology codes, respectively. Pri-
mary outcomes were mortality and limb salvage. Bivariate associations were
tested using the c2 test, and predictors were identiﬁed using Cox regression
models.
Results: A total of 12,029 incident dialysis patients underwent LER
(24% endo, 76% open). CLI was the indication in 79.9% of endo LER,
and 72.8% of open LER. The major amputation rate #30 days for CLI pa-
tients was 15.1% (15.7% endo, 13.1% open; P ¼ .002) and for claudicant
patients was 5.2% (5.2% endo, 4.9% open; P ¼ .771). At 1 year, 32.0% of
CLI patients (33.0% endo, 29.1% open; P < .001) and 14.4% of claudicant
patients (14.0% endo, 16.4% open; P ¼ .254) had undergone a major ampu-
tation. The mortality rate at 30 days for CLI patients was 7.8% (7.2% endo,
9.8% open; P ¼ .001) and for claudicant patients was 5.2% (4.7% endo, 7.9%
open; P ¼ .018). At 1 year, the mortality rate was 38.4% for CLI patients
(37.6% endo, 40.9% open; P ¼ .005) and 25.7% for claudicant patients
(25.7% endo, 25.2% open; P ¼ .820). There were no signiﬁcant differences
between estimated survival for endo and open procedures at 1 year when
stratiﬁed by clinical indication. Estimated limb salvage differed signiﬁcantly
between open and endo LER only among CLI patients, with open LER
associated with improved limb salvage (P ¼ .001; Fig). Signiﬁcant pre-
dictors of post-LER mortality were older age (P < .001) and congestive
heart failure (P < .001).
Conclusions: Mortality and amputation rates after LER for dialysis
patients are signiﬁcant, particularly for patients with CLI. Although open
LER is associated with improved limb salvage compared with endo LER,
mortality is greater at 30 days and 1 year. Given the high overall mortality
rates, the presence of dialysis-dependence questions the indication for LER,
especially for claudication.
Fig. Amputation survival rates by indication and type of
intervention.Long-Term Results for Primary Bypass Versus Primary Angioplasty/
Stent for Lower Extremity Critical Limb Ischemia
Jeremy D. Darling, BA, Lindsey Korepta, MD, Thomas Curran, MD, John
C. McCallum, MD, Dominique Buck, MD, Elliot L. Chaikof, MD, Raul J.
Guzman, MD, Mark C. Wyers, MD, Allen Hamdan, MD, Marc L.
Schermerhorn, MD. Beth Israel Deaconess Medical Center, Boston, Mass
Objectives: Long-term results comparing percutaneous transluminal
angioplasty 6 stent (PTA/S) and surgical bypass grafting (BPG) for critical
limb ischemia (CLI) in patients who have had no prior intervention
have not been extensively reported. We detail our results with 3-year
follow-up.
Methods: We reviewed all lower extremity revascularization proce-
dures at our institution from January 2005 to December 2010, where
927 patients presented for CLI and underwent a ﬁrst-time intervention.
Outcomes included complications, restenosis, symptom recurrence, reinter-
ventions, minor and major amputations, and mortality. Predictors for
reintervention and amputation were identiﬁed using a Cox regression
model.
Results: Of the 927 patients, 519 underwent BPG and 408 under-
went PTA/S. BPG were above the knee in 58% (40% vein) and below
the knee in 42% (100% vein). Mean age was 70.5 years (BPG) vs 72.4 years
(PTA/S; P ¼ .03), with more males undergoing BPG (64% vs 52%; P <
.01). Mean length of stay was 10 days for BPG vs 7.4 days for PTA/S (P
¼ .02), with 3-year reintervention rates signiﬁcantly lower in patients under-
going BPG (42% vs 54%; P < .01). There were no differences in perioper-
ative mortality (3% vs 2%; not signiﬁcant). Wound infection was 11% in BPG
patients; however, BPG showed improved freedom from restenosis of 78%
vs 67% at 3 years (odds ratio [OR], 1.6; 95% conﬁdence interval [CI], 1.2-
2.1). A Cox regression model of all patients showed that a reintervention
#3 years was predicted by PTA/S (OR, 1.6; 95% CI, 1.1-2.3; Fig) and a
history of smoking (OR, 1.3; 95% CI, 1.0-1.6). Major amputations were
predicted by gangrenous indications (OR, 1.9; 95% CI, 1.1-3.5) and were
not predicted by procedure type.
Conclusions: BPG for the primary treatment of CLI showed
improved freedom from restenosis and signiﬁcantly fewer reinterventions
than PTA/S #3 years but was associated with increased length of stay
and wound infection. Perioperative mortality and 3-year amputation rates
were similar between procedure types.
Fig. Freedom from reintervention.
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Objectives: Acute lower extremity ischemia secondary to thrombo-
embolism is a common problem treated by vascular surgeons. Contem-
porary data regarding this problem are sparse. This report examines a
10-year single-center experience with acute lower extremity thrombo-
embolism and describes the surgical management and outcomes
observed.
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tremity embolization from January 2002 to September 2012 were identiﬁed
using International Classiﬁcation of Diseases-9th Revision and Current Pro-
cedural Terminology codes. Iatrogenic cases and cases secondary to
trauma were excluded. Demographic, comorbidity, presentation, opera-
tive management, postoperative morbidity, and mortality data were
abstracted from the electronic medical record. Data were examined using
count (%), median, or mean 6 standard deviation, and product-limit sur-
vival analysis.
Results: The identiﬁed study sample included 170 patients (47% fe-
male). Mean age was 69 years, and 80% were white. Eighty-two patients
(49%) had a known history of atrial ﬁbrillation, and four (2%) had a
warfarin-associated international normalized ratio $2.0. Eighty-three
percent presented >6 hours after symptom onset. Nine percent presented
with a concurrent stroke. Femoral artery exposure for embolectomy was
the preferred initial mode of treatment. Additional popliteal exposure for
inadequate clearance of tibial occlusion was required in 4% of cases, 10%
of cases used a popliteal-only approach for isolated distal occlusions, and
local instillation of thrombolytic agents was used in 16% of cases. Fascioto-
mies were performed in 39% of cases. An unexpected return to the operating
room occurred in 24% of cases. Eleven patients (6%) required bypass for
limb salvage during the initial hospitalization. Amputation was required dur-
ing the index hospitalization in 26 patients (15%) and after initial discharge
in an additional six patients (4%). In-hospital or 30-day mortality was 18%.
Median length of stay was 8 days, and 34% of patients required discharge to
a skilled facility. Recurrent embolization occurred during follow-up in 23
patients (14%) at a median interval of 1.6 months. Amputation-free and
overall survival estimates for the study sample at 5 years were 75% and
49%, respectively.
Conclusions: Despite advances in contemporary medical care, lower
extremity arterial embolization remains a condition that is associated with
signiﬁcant morbidity and mortality. Furthermore, the condition is resource
intensive to treat and could be prevented (either initially or in recurrence) in
a substantial subset of patients.
Trends in the Utilization and Cost of Ambulatory Endovascular
Procedures
Thomas Curran, MD, John McCallum, MD, Dominique Buck, MD,
Jeremy Darling, BA, Raul J. Guzman, MD, Mark Wyers, MD, Allen
Hamdan, MD, Elliot Chaikof, MD, PhD, Marc Schermerhorn, MD. Beth
Israel Deaconess Medical Center, Boston, Mass
Objectives: Endovascular therapy is used increasingly for the treat-
ment of claudication and limb threat from peripheral arterial disease
(PAD). These procedures may be performed in inpatient hospital-associated
ambulatory or freestanding ambulatory settings, although utilization and
costs in the ambulatory setting have not been studied. We aim to evaluate
trends in the utilization and cost of endovascular procedures across health
care settings.
Methods: The State Ambulatory Surgery Databases (SASD) and State
Inpatient Databases (SID) of Florida, New Jersey, California, and Maryland
from 2005 to 2009 were queried for patients undergoing elective endovas-
cular procedures for PAD. Utilization trends for these procedures were
stratiﬁed by indication (claudication vs critical limb ischemia [CLI]) and ser-
vice location (freestanding ambulatory, hospital-associated ambulatory,
inpatient). Because freestanding data were available for Florida only, com-
parison of health care charges across locations was restricted to this state.
Inpatient charges for cases with length of stay >1 day were excluded
from cost analysis.
Results: We identiﬁed 101,910 procedures: 64,722 (64%) for claudi-
cation and 37,188 (36%) for CLI. Overall procedure volume increased 57%
from 2005 to 2009. Utilization of ambulatory facilities (freestanding and
hospital-associated) for claudication increased 84% from 2005 to 2009
(6188 to 11,547), whereas inpatient procedures declined 11% from peak
utilization in 2007 to 2009 (4421 to 3947). Freestanding procedures for
claudication showed the most pronounced increase, with 444% (47 to
256) during the study period. Procedures for CLI increased in all service lo-
cations (ambulatory: 2606 to 4936, 89%; inpatient: 3173 to 3619, 14%).
Total charges for treatment of claudication in freestanding centers were
only 53% of hospital-associated ambulatory centers ($14,727 vs $27,945),
whereas total charges for treatment of CLI were similar in freestanding vs
hospital associated ambulatory centers ($26,704 vs $27,072). Inpatient
charges far exceeded both ambulatory locations (claudication: $39,900;
CLI: $41,368).
Conclusions: Freestanding and hospital-associated ambulatory endo-
vascular procedure utilization is increasing for both claudication and CLI.
Treatment of claudicant patients in freestanding centers appears to be
particularly cost-effective.Fig. Annual endovascular case volume by indication and proce-
dure site.
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Objectives: Surgical revascularization for lower limb ischemia re-
mains an important component for optimization of quality of life and
symptomatology in patients with peripheral arterial disease. The
objective of this meta-analysis is to establish which prosthetic graft,
Dacron or polytetraﬂuoroethylene (PTFE), has the better long-term
patency in patients undergoing an above-knee femoropopliteal arterial
bypass.
Methods: This meta-analysis was performed using Cochrane and
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines. An electronic search of all relevant databases was per-
formed from 1990 to 2013 using the Medical Subject Headings: “Dacron,”
“PTFE,” “above knee,” “femoropopliteal,” and “bypass.” The inclusion
criteria were randomized controlled trials, use of Dacron vs PTFE prosthetic
conduits, and completion of an above-knee femoropopliteal arterial bypass
involving adult patients aged >18 years presenting with disabling claudica-
tion, rest pain, or tissue loss, occlusion of the superﬁcial femoral artery, and
reconstitution of the above-knee popliteal artery. Graft patency rates were
calculated using RevMan 5.1 software. When multiple studies were evalu-
ated, original patency rates were documented when only one study result
was available.
Results: Ninety-one publications were reviewed. After exclusion of
duplicate, nonrandomized, and alternative bypass surgery studies, four
randomized controlled trials were identiﬁed involving 957 patients
comprising 476 Dacron and 481 PTFE above-knee lower limb arterial
bypasses. Mean age reported was 66 years, and all patients had general-
ized cardiovascular comorbidities and risk factors. Two studies evaluated
6-mm grafts, one assessed 8-mm grafts, and the other study included
graft sizes between 5 mm and 8 mm. Although primary and secondary
patency rates at 12 months were not signiﬁcantly different (RR, 0.47;
P ¼ .52 and RR, 0.84; P ¼ .52), 24- and 60-month primary patency
rates were better with Dacron compared with PTFE grafts (RR, 0.81;
P ¼ .03; and 52% vs 36%; P ¼ .04). Statistical analysis also supported
higher secondary patency rate for Dacron at 24 months (RR, 0.75; P
¼ .02) and 60 months (70% vs 51%; P ¼ .01). Ten-year patency rates
were similar. Antiplatelet/anticoagulation therapy was prescribed in
85% of patients in one trial. However, exact best medical therapy strate-
gies were not described in the other studies. There was no difference in
amputation, overall morbidity, or mortality rates between the two surgi-
cal graft populations.
Conclusions: Current evidence suggests that Dacron prosthetic grafts
are superior to PTFE grafts in above-knee femoropopliteal arterial bypass
procedures. Further randomized trials targeting standardization of con-
founding variables, particularly graft size and best medical therapy, are
warranted.
